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Abstract
Background: The aim of this study was to determine the effect of gestational age on pharmacokinetics of
ranitidine in newborns with gastroesophageal reflux.
Methods: A prospective, descriptive and pharmacokinetic study was carried out in 30 pre-term and 20 full-term
babies. 3 mg/kg of ranitidine was administered intravenously to all the babies and at 0.25, 0.5, 1, 2, 4, and 8 h
following the administration, samples of blood were drawn to assess ranitidine levels using high performance liquid
chromatographic technique.
Results: Pharmacokinetics of ranitidine had a bi-exponential behavior with a half-life elimination of (t1/2el) 2.79 h,
area under curve (AUC) of 1688 ng/mL, volume of distribution (Vd) of 1.44 L/kg, and clearance (Cl) of 5.9 L/kg/h.
The median plasmatic concentration in pre-terms was 1113 ng/mL and 280 ng/mL in full-terms. Vd, t1/2 and Cl
presented high values in preterm although the correlation of Cl with glomerular filtration in term newborns was
better.
Conclusions: Plasma levels of ranitidine depend on the gestational age of the newborns. However, the possible
relationship between after-birth age and pharmacokinetics of the neonates as their internal organs get matured
without minding their gestational background.
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Background
Ranitidine decreases gastric acid secretion and improves
esophagitis. It is then fundamental to have a good know-
ledge of its pharmacokinetic activities so as to make the
best use of it in the treatment of every patient [1–4]. In
normal newborns and infants, several organ systems
progressively get matured to culminate in the later life
and progressive maturation depends on the organ sys-
tem and the specific iso-enzyme involved [5, 6]. In a
study by Hedenström et al., [7], on pharmacokinetics of
ranitidine in adults, it was found that the use of multiple
dosing scheme of ranitidine has similar parameters as
the use of single dosing scheme. Its concentration,
following intravenous administrations fits to a bi-
exponential kinetics. In nonates, the half-life elimination
is almost 2 h, and it is a little more prolonged after oral
administration [8]. Hepatic metabolism is one of the
elimination route and this suggests that the drug has en-
terohepatic re-circulation for bi-exponential rate [9].
Due to the high risk of either overdosing or under-
dosing in newborns, which could lead to either thera-
peutic failure or toxic effect, the study of pharmacokin-
etics of ranitidine in this group of patients is very
important [1, 10, 11]. The absence of specific ranitidine
dosing scheme for newborns has cornered physicians to
use doses obtained by modifying the dosing schemes for
older and mature children. The result of this is usually
overdosing or sub-therapeutic dosing scheme.
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In a study of pharmacokinetics of ranitidine in 27 full-
term newborns without liver or kidney problems using
2.4 mg/kg of ranitidine, Fontana et al., [12], found that
the half-life elimination (t1/2el) of the drug was 3.45 ±
0.31 h, the total distribution volume (Vd) was 1.52 ±
0.91 L/kg and the total plasmatic clearance (CL) was
5.02 ± 0.46 mL/kg/h. However, the above study did not
consider preterm neonates. Assuming that these mea-
surements do not change with different dosing schemes,
they could be used to derive a treatment plan for new-
born, since the age-specific pharmacodynamics could
only be evaluated after knowing the age-specific
pharmacokinetics.
In view of the above findings, the aim of this study
was to determine the effect of gestational age on
pharmacokinetics of ranitidine in newborns with gastro-
esophageal reflux to provide guidance on ranitidine
therapeutic schemes for this age group.
Methods
A prospective, descriptive and pharmacokinetic study of
50 newborns (30 males and 20 females) receiving raniti-
dine at Neonatal Intensive Care Unit (NICU), General
Hospital, Durango, Mexico, was carried out with the ob-
jective of determining the pharmacokinetics of the drug.
All the patients, by medical prescription, required
treatment with ranitidine. To avoid nephrotoxicity,
serum creatinine and its renal clearance were deter-
mined as an inclusion criterion and once the values were
confirmed to be normal, the patients were made to re-
ceive a first dose consisting of 3 mg/kg/day of ranitidine
by slow intravenous injection (during two min) of mul-
tiple doses. A sample of 0.5 mL of whole blood was
drawn from neonates at 0.25, 0.5, 1, 2, 4, and 8 h follow-
ing drug administration, and were separated by centrifu-
gation and stored for no more than 30 days at −80 °C
until analysis. However during the validation procedure
the samples assayed showed stability for at least 60 days.
During the study intragastric pH was registered by
gastric aspirates. The research protocol was approved by
the Research Ethics Committee of the General Hospital
of Durango, México, and informed consent was obtained
from the parent or guardian of each patient, according
to principles of Helsinki Declaration of 1975. Acceptance
into the study did not involve greater risks than those
related to sampling. The volume was minimal and did
not put at risk the balance or imbalance of fluids. The
sample size was calculated using the formula reported
by Castilla and Cravioto [13].
Pre-term and full-term neonates of 0 to 28 days old
that required ranitidine treatment with normal liver and
kidney functions were included in the study. All patients
requiring treatment with ketoconazole or antacids agents
were excluded.
Analytical procedure
Plasma ranitidine concentrations were analyzed using
High performance liquid chromatography (HPLC), Agi-
lent 1100 chromatographic system. The method was
adapted from a previously published method by Casta-
ñeda et al., [14]. Quantification was carried out by using
the ratio of area under the curve for ranitidine and niza-
tidine as standard internal calibration curves, and linear-
ity was assessed in concentrations of 0, 50, 100, 250,
500, 1000 and 1500 ng/mL for solution and plasma. A
correlation coefficient of r = 0.999 was determined be-
tween intra and interday.
Mean accuracy of known concentration ranged from
99.4 to 103.5 %. Recovery was assessed by determining
three concentration levels in plasma and solution (75,
600, and 1200 ng/mL). The minimal concentration that
could be accurately measured was 15 ng/mL. A coeffi-
cient of variation (CV) of less than 7 % was obtained.
The percentage of recovery was 108 %, which is within
the range recommended by Official Mexican Standard
[15]. The response of plasma samples, to which raniti-
dine had been added at the afore-mentioned concentra-
tions was compared with the response of ranitidine
solutions at the same concentrations.
To 200 mcL of plasma, 50 mcL of Nizatidine (internal
standard) and 50 mcL of NaOH 2.5 M were added. The
mixture was lightly shaken in vortex and then 3 mL of
dichloromethane was added to it and shaken again for
1 min in vortex, and centrifuged for 5 min at 3000 rpm.
Once centrifuged, the organic phase was separated from
the aqueous phase and air-evaporated at a temperature
of 45 °C. It was then reconstructed with 200 mcL of mo-
bile phase, and 50 mcL of this mobile phase was injected
to the system [14]. A chromatographic symmetry C18 of
5 μm and UV detector with diode arrangement with
flow velocity of 1 mL/min at a wavelength of 313 nm
was used. For mobile phase, a mixture of monobasic po-
tassium phosphate 0.05 M, pH 6.5 and acetonitrile (88/
12, v/v) was used, with an injection volume of 100 mcL.
The retention time of ranitidine was 2.82 min, 4.2 for IS
and 6.5 as total chromatographic run time.
The pharmacokinetic profile of ranitidine was esti-
mated in plasma concentrations obtained at different
times [16]. Non-linear regression was used to fit plasma
ranitidine concentrations to a two-compartment (bi-ex-
ponential) model [17]. The WinNonlin software (Ver-
sion 2) [18], was used for all non-linear regression, and
to generate all pharmacokinetic parameters. A similar
analysis was performed with observations either in pre-
term or term cases.
Results
Fifty newborns that were admitted at Neonatology Unit
of Hospital General de Durango, Mexico that required
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therapeutic management with ranitidine were studied.
All newborns presented risk factors susceptible to di-
gestive tract bleeding.
The characteristics of the patients based on gestational
age were as follows: 6 pre-term babies (babies born be-
fore 37 weeks of gestation) and small for their gesta-
tional age (SGA) (weight < 10th percentile); 20 pre-terms,
appropriate for their gestational age (AGA) (weight be-
tween 10 and 90 percentile); 4 pre-terms, large for their
gestational age (LGA) (weight > 90 percentile); 7 full-
terms (babies born between 37 and 42 weeks), small for
their gestational age (SGA); and 13 full-terms, appropri-
ate for their gestational age (AGA). Table 1 shows a
comparative analysis of the statistically significant differ-
ences between gestational age and birth weight of pre-
term and term. It can be observed that the values in
preterm newborns were much lower (Latin American
consensus) [19].
The average value and standard deviation of the gesta-
tional age were 34.2 ± 4.16 weeks for female newborns
and 35.8 ± 2.7 weeks for males (p = 0.103). However,
even when the birth weights were different in the male
and female newborns with average value of 2330.7 ±
677 g for girls and 2,680.5 ± 661 for boys, there was no
statistically significant difference p = 0.715. In all the pa-
tients, there were no clinical signs or laboratory evidence
of renal and/or liver dysfunctions. The pharmacokinetic
profiles of the preterm as well as the term neonates are
shown in Fig. 1.
Plasma concentration data were fit to a two compart-
ment (bi-exponential) model after the applications of re-
sidual methods. The calculated pharmacokinetic
parameters are reported in Table 2.
In Table 3, the median, minimum, and maximum
values of plasma concentration of ranitidine of the new-
borns based on gestational age are shown.
Although, the number of cases is different considering
the gestational age, the highest number of subjects cor-
responded to AGA pre-term newborns (20 cases), and
the least to LGA pre-terms (4 cases). These two groups
presented the most elevated concentration values of ra-
nitidine at zero hour with median value of 1484 ng/mL
and 1337 ng/mL respectively.
In the case of intravenous single dose, the plasma con-
centration of ranitidine was ≥ 400 ng/mL in 34 (68 %) of
the newborns. Concentrations within the normal
therapeutic range (100–400 ng/mL) were seen in 11
(22 %) of the neonates while 5 (10 %) had concentrations
below sub-therapeutic range (<100 ng/mL). The analysis
showed statistically significant differences with X2 =
28.12 and p ≤ 0.01. There is a wide variation in the
plasma concentration of ranitidine which decreases as
the gestational age increases. This explains the variability
in ranitidine plasma concentration in early gestational
age.
Within the first 30 min, the pH value of all the pa-
tients was ≤ 4. There was an increase of > 5, with the
intragastric pH being > 4 in a minimum of 15 h, which
was registered during the study by gastric aspirates.
Discussion
Ranitidine is a drug used in the treatment of digestive
tract bleeding, primarily in the upper segment, due to
mucus alteration during neonatal stage. In addition, it is
highly used in the prevention of gastric bleeding in neo-
nates requiring therapeutic management in intensive
care units. However, studies on PK of this drug in a risk
group like newborns are very scarce. This is the basis
justifying this study.
Fontana et al. [20], on studying PK values of ranitidine
in term neonates reported t½el values of 3.45 ± 0.31 h;
Vd, of 1.52 ± 0.91 L/kg; and Cl of 5.02 ± 0.46 mL/kg/h.
Wiest et al. [21], on their part reported t½el values of
2.09 h; Vd, of 1.61 L/kg; and Cl of 13.9 mL/kg/h in neo-
nates from 2 to 21 months of age. A comparison of Vd
values in both studies with 1.6 L/kg reported in adults
by Schaiquevich et al., [22], reveals that plasma protein
binding and tissue distributions of this drug are similar
in different age groups.
The value of t½el in the study of Fontana et al. [20],
was more prolonged than that reported by Wiest et al.
[21] (3.45 vs 2.09 h). Consequently, Cl was less (5.02 vs
13.9 mL/kg/h). In a study carried out by Mallet et al. [4],
t½el value of 2.8 h was obtained in neonates of 6 weeks
to 6 months old while in other studies made in older ne-
onates by Zhang et al., [23] and in adult by Schaiquevich
et al., [22], t½el values of 1.8 and 1.9 h respectively were
reported. These evidentially depict that the most pro-
longed t½el value reported in newborns precisely reflects
the lowest glomerular filtration velocity different from
what is observed in older neonates where t½el values
Table 1 Demographic data of newborns whose pharmacokinetic of ranitidine were studied





n = 20 n = 30 n = 30 n = 20
Gestational age (weeks) Mean ± SD 34.2 ± 4.16 35.8 ± 2.7 2.76 0.103 33.6 ± 3.7 38.3 ± 0.9 0.0001
Birth weight (g) Mean ± SD 2330.7 ± 677 2680.5 ± 561 0.135 0.715 2361.9 ± 563.0 3000.8 ± 620 0.008
SD standard deviation
*Square Chi Test (X2)
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were found to increase in the first three weeks of neo-
natal life [24].
The use of ranitidine with other drugs in a disease
such as gastro-esophageal reflux is common. Gastro-
esophageal reflux is a common sickness of upper gastro-
intestinal motility that widely differs in severity and
prognoses. The knowledge of ranitidine pharmacokinet-
ics and other drugs that are usually combined with it for
the treatment of this pathology is important, this would
help to optimize the therapeutic benefits. Patients with
gastro-esophageal reflux are usually elderly people and
the pharmacokinetic variability in this group of popula-
tion is evident. Moreover, the gastro-esophageal reflux,
the basal pathology, is usually accompanied by symp-
toms and other pathologies that require medical man-
agement with other compounds. The ideal therapy for
esophageal reflux should have a linear pharmacokinetic
and a relatively longer plasma half-life (t½el), a duration
that would permit its administration once a day, as well
as a stable effect independent of its interactions with
food, antacids and other drugs. In the present study,
total clearance of ranitidine was well correlated with
glomerular filtration velocity. An administration of ra-
nitidine (3 mg/kg/24 h) for 72 h was reduced for 24 h,
suggesting that in full-term newborns with stable hepatic
and liver functions, the administration of ranitidine
needs not be more frequent than 12 h, and that the
treatment response must be monitored with repeated
measurement of gastric pH and the doses adjusted in
conformity with the response obtained.
This study would permit the determination and identi-
fication of ranitidine concentrations in newborn patients.
Kuusela, [25] studied critically ill pre-term and full-term
newborns to determine the optimum ranitidine doses
through gastric pH monitoring. The same was investi-
gated by Fontana et al. [12]. Their results showed that
critically ill newborns were able to secrete intraluminal
gastric acid, and that ranitidine concentrations corre-
lated with gastric pH values ≥ 4. They concluded that a
significantly lower dose of ranitidine is needed in pre-
Fig. 1 Pharmacokinetics of ranitidine in preterm (top line) and term (bottom line) neonates after intravenous dose of 3 mg/kg
Table 2 Pharmacokinetic parameters after data adjustment for a
model of two compartments for full population. Average ±
standard deviation
AUC (Area under curve) 1688.9 ± 562.6 ng/mL/h
t½ of K10 1.69 ± 0.56 h
t½ α (Half life distribution) 0.3899 ± 0.129 h
t½ el (Half life elimination) 2.79 ± 0.93 h
K10 (Velocity constant) 0.9105 ± 0.34 h
−1
K12 (Velocity of transference) 0.5395 ± 0.176 h
−1
K21 (Velocity of transference) 1.76 ± 0.58 h
−1
Vd (Volume of distribution) 1.44 ± 0.48 L/Kg
Cl (Clearance) 5.9 ± 1.96 mL/Kg/h
Table 3 Median, minimum and maximum values of plasma
concentrations of ranitidine (ng/ml) in newborns of both sexes,






SGA Pre-term 6 518 197.66 937.6
AGA Pre-term 20 1484 61.20 7817.6
LGA Pre-term 4 1337 684.18 3687.9
SGA term 7 217 55.39 3080.7
AGA term 13 343 45.94 1075.7
a Classification according to Jurado García (15)
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term compared to full-term newborns in order to main-
tain their intraluminal gastric pH over 4.
The prevailing adjusted doses on prescription of
this drug for newborn patients have the disadvantage
of either sub-therapeutic concentration levels or con-
centration levels with high risk of overdosing [26].
Therefore, the identification of these concentrations is
of paramount importance if we want to get the max-
imum therapeutic benefit. The results of the present
study suggest a modification in the treatment regi-
mens in Neonatology service of General Hospital of
Durango, Mexico, as was recommended in previous
studies [27, 28].
Conclusions
Plasma levels of ranitidine depend on the gestational age
of a newborn. At the same time, the results could con-
tribute to a rational management of ranitidine.
It is inferred the possible relationship between after-
birth age and pharmacokinetics of the neonates as their
internal organs get matured without minding their ges-
tational background.
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